302 related articles for article (PubMed ID: 14621044)
21. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
Rzepecki P; Sarosiek T; Szczylik C
Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840
[TBL] [Abstract][Full Text] [Related]
22. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.
Srinivasan R; Takahashi Y; McCoy JP; Espinoza-Delgado I; Dorrance C; Igarashi T; Lundqvist A; Barrett AJ; Young NS; Geller N; Childs RW
Br J Haematol; 2006 May; 133(3):305-14. PubMed ID: 16643433
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic stem cell transplantation for severe aplastic anemia: graft rejection remains a problem.
Aki SZ; Sucak GT; Ozkurt ZN; Yeğin ZA; Yağci M; Haznedar R
Transfus Apher Sci; 2009 Feb; 40(1):5-11. PubMed ID: 19121979
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of conditioning regimens containing or no fludarabine in nonmyeloablative allogeneic peripheral blood stem cell transplantation].
Guo M; Yu CL; Wang DH; Qiao JH; Sun WJ; Shi BF; Zhang S; Sun QY; Yao B; Ai HS
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):413-5. PubMed ID: 14642178
[TBL] [Abstract][Full Text] [Related]
25. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Schetelig J; Bornhäuser M; Kiehl M; Schwerdtfeger R; Kröger N; Runde V; Zabelina T; Held TK; Thiede C; Fauser AA; Beelen D; Zander A; Ehninger G; Siegert W;
Bone Marrow Transplant; 2004 Mar; 33(5):483-90. PubMed ID: 14716342
[TBL] [Abstract][Full Text] [Related]
26. The use of a fludarabine-based conditioning regimen in patients with severe aplastic anemia--a retrospective analysis from three Indian centers.
George B; Mathews V; Lakshmi KM; Melinkeri S; Sharma A; Viswabandya A; Sharma S; Das S; Ahmed R; Abraham A; Nair V; Apte S; Chandy M; Srivastava A
Clin Transplant; 2013; 27(6):923-9. PubMed ID: 24304374
[TBL] [Abstract][Full Text] [Related]
27. Management of adult patients older than 40 years refractory to at least one immunosuppressive course: HLA-identical sibling HSCT using fludarabine-based conditioning.
Maury S; Aljurf M
Bone Marrow Transplant; 2013 Feb; 48(2):196-7. PubMed ID: 23222386
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of acquired severe aplastic anemia in pediatric patients with immunosuppression and allogeneic stem cell hematopoietic transplant].
Barriga C F; Wietstruck P A; Becker K A; Zúñiga C P; Besa De C P; Alvarez Z M; Ocqueteau T M; Bertín C P
Rev Med Chil; 2007 Nov; 135(11):1421-8. PubMed ID: 18259653
[TBL] [Abstract][Full Text] [Related]
31. Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling.
Mori T; Koh H; Onishi Y; Kako S; Onizuka M; Kanamori H; Ozawa Y; Kato C; Iida H; Suzuki R; Ichinohe T; Kanda Y; Maeda T; Nakao S; Yamazaki H
Int J Hematol; 2016 Apr; 103(4):461-8. PubMed ID: 26910242
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic stem cell transplantation from related and unrelated donors for aplastic anaemia in adults--a single-centre experience.
Buchholz S; Dammann E; Koenecke Ch; Stadler M; Franzke A; Blasczyk R; Bremer M; Krauter J; Hertenstein B; Ganser A; Eder M
Ann Hematol; 2008 Jul; 87(7):551-6. PubMed ID: 18386010
[TBL] [Abstract][Full Text] [Related]
33. Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.
Maschan AA; Trakhtman PE; Balashov DN; Shipicina IP; Skorobogatova EV; Skvortsova YV; Dyshlevaja ZM; Samochatova EV; Rumiantsev AG
Bone Marrow Transplant; 2004 Aug; 34(4):305-7. PubMed ID: 15195080
[TBL] [Abstract][Full Text] [Related]
34. [Hematopoietic stem-cell transplantation in aplastic anemia].
Hernández-Rivera EG
Rev Invest Clin; 2005; 57(2):298-304. PubMed ID: 16524071
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma -- single center experience.
Rzepecki P; Zolnierek J; Sarosiek T; Langiewicz P; Szczylik C
Neoplasma; 2005; 52(3):238-42. PubMed ID: 15875086
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
Inamoto Y; Suzuki R; Kuwatsuka Y; Yasuda T; Takahashi T; Tsujimura A; Sugimoto K; Oba T; Terakura S; Atsuta Y; Murata M; Ito M; Kodera Y; Miyamura K
Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
[TBL] [Abstract][Full Text] [Related]
37. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
Chaudhury S; Auerbach AD; Kernan NA; Small TN; Prockop SE; Scaradavou A; Heller G; Wolden S; O'Reilly RJ; Boulad F
Br J Haematol; 2008 Mar; 140(6):644-55. PubMed ID: 18302713
[TBL] [Abstract][Full Text] [Related]
38. Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies.
Kang HJ; Hong KT; Lee JW; Kim H; Park KD; Shin HY; Lee SH; Yoo KH; Sung KW; Koo HH; Lee JW; Chung NG; Cho B; Kim HK; Koh KN; Im HJ; Seo JJ; Jung HJ; Park JE; Lee YH; Lim YT; Lim YJ; Kim SY; Yoo ES; Ryu KH; Lee JH; Park JA; Park SK; Ahn HS;
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1455-1459. PubMed ID: 27090956
[TBL] [Abstract][Full Text] [Related]
39. Cyclophosphamide and antithymocyte globulin conditioning may be sufficient for Korean patients with early stage severe aplastic anemia transplanted with marrow from donors other than HLA-identical siblings.
Lee JH; Lee JH; Lee JS; Kim WK; Chi HS; Lee KH
Haematologica; 2001 Apr; 86(4):434-5. PubMed ID: 11325653
[TBL] [Abstract][Full Text] [Related]
40. [Bone marrow transplantation for severe aplastic anemia].
Bullorsky EO; Bonduel M; Shanley C; Figueroa C; Stemmelin G; Del Pozo A; Ceresetto J; Delfino S; Puppo M; Muriel FS
Medicina (B Aires); 1998; 58(2):130-4. PubMed ID: 9706244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
